Heart-specific expression of FGF-16 and a potential role in postnatal cardioprotection

Cytokine and Growth Factor Reviews

Volumn 26, Issue 1, 2015, Pages 59-66

  Wang, Jie ^a   Sontag, David ^a   Cattini, Peter A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardioprotection; Embryonic and postnatal heart; Endocardium; FGF 16; Myocardium

Indexed keywords

E1A ASSOCIATED P300 PROTEIN; FIBROBLAST GROWTH FACTOR 16; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MYOCYTE ENHANCER FACTOR 2; PROTEIN KINASE B; PROTEIN KINASE C; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; FGF16 PROTEIN, HUMAN; FGF16 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; STOP CODON;

AMINO ACID SEQUENCE; ANIMAL CELL; BINDING SITE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHROMATIN STRUCTURE; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; ENDOCARDIUM; GENE CONTROL; HEART DEVELOPMENT; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; MOUSE; NONHUMAN; NONSENSE MUTATION; PERINATAL PERIOD; PHENOTYPE; PHENOTYPIC VARIATION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SHORT SURVEY; SIGNAL TRANSDUCTION; X CHROMOSOME; ANIMAL; CARDIOVASCULAR DISEASES; EMBRYOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEART; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; PREGNANCY; RAT; RISK FACTOR; STOP CODON; TATA BOX;

MURINAE; MUS; RATTUS;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CODON, NONSENSE; EMBRYONIC DEVELOPMENT; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HEART; HUMANS; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; PREGNANCY; PROMOTER REGIONS, GENETIC; RATS; RISK FACTORS; TATA BOX;

EID: 84923002546     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.07.007     Document Type: Short Survey

References (78)

1. Poole T.J., Finkelstein E.B., Cox C.M. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn 2001, 220:1-17.
2. Gu T., Niu X., Cheng D. The effect of different way of using FGF on wound healing. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 1997, 11:261-263.
3. Itoh N., Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004, 20:563-569.
4. Kettunen P., Furmanek T., Chaulagain R., Kvinnsland I.H., Luukko K. Developmentally regulated expression of intracellular Fgf11-13, hormone-like Fgf15 and canonical Fgf16, -17 and -20 mRNAs in the developing mouse molar tooth. Acta Odontol Scand 2011, 69:360-366.
5. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol 2001, 2. REVIEWS3005.
6. Ago H., Kitagawa Y., Fujishima A., Matsuura Y., Katsube Y. Crystal structure of basic fibroblast growth factor at 1.6A resolution. J Biochem 1991, 110:360-363.
7. Zhu X., Komiya H., Chirino A., Faham S., Fox G.M., Arakawa T., et al. Three-dimensional structures of acidic and basic fibroblast growth factors. Science 1991, 251:90-93.
8. Ornitz D.M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000, 22:108-112.
9. Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 2000, 101:413-424.
10. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009, 8:235-253.
11. Szebenyi G., Fallon J.F. Fibroblast growth factors as multifunctional signaling factors. Int Rev Cytol 1999, 185:45-106.
12. Baron O., Forthmann B., Lee Y.W., Terranova C., Ratzka A., Stachowiak E.K., et al. Cooperation of nuclear fibroblast growth factor receptor 1 and Nurr1 offers new interactive mechanism in postmitotic development of mesencephalic dopaminergic neurons. J Biol Chem 2012, 287:19827-19840.
13. Stachowiak M.K., Maher P.A., Joy A., Mordechai E., Stachowiak E.K. Nuclear accumulation of fibroblast growth factor receptors is regulated by multiple signals in adrenal medullary cells. Mol Biol Cell 1996, 7:1299-1317.
14. Lu S.Y., Sontag D.P., Detillieux K.A., Cattini P.A. FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development. Am J Physiol Cell Physiol 2008, 294:C1242-C1249.
15. Sontag D.P., Cattini P.A. Cloning and bacterial expression of postnatal mouse heart FGF-16. Mol Cell Biochem 2003, 242:65-70.
16. Chamorro M.N., Schwartz D.R., Vonica A., Brivanlou A.H., Cho K.R., Varmus H.E. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 2005, 24:73-84.
17. Urso C., Caimi G. Oxidative stress and endothelial dysfunction. Minerva Med 2011, 102:59-77.
18. Kant R., Diwan V., Jaggi A.S., Singh N., Singh D. Remote renal preconditioning-induced cardioprotection: a key role of hypoxia inducible factor-prolyl 4-hydroxylases. Mol Cell Biochem 2008, 312:25-31.
19. Leychenko A., Konorev E., Jijiwa M., Matter M.L. Stretch-induced hypertrophy activates NFkB-mediated VEGF secretion in adult cardiomyocytes. PLoS ONE 2011, 6:e29055.
20. Santos D.G., Resende M.F., Mill J.G., Mansur A.J., Krieger J.E., Pereira A.C. Nuclear factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure. BMC Med Genet 2010, 11:89.
21. Hotta Y., Sasaki S., Konishi M., Kinoshita H., Kuwahara K., Nakao K., et al. Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Dev Dyn 2008, 237:2947-2954.
22. Lu S.Y., Sheikh F., Sheppard P.C., Fresnoza A., Duckworth M.L., Detillieux K.A., et al. FGF-16 is required for embryonic heart development. Biochem Biophys Res Commun 2008, 373:270-274.
23. Lavine K.J., Yu K., White A.C., Zhang X., Smith C., Partanen J., et al. Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. Dev Cell 2005, 8:85-95.
24. Miyakawa K., Imamura T. Secretion of FGF-16 requires an uncleaved bipartite signal sequence. J Biol Chem 2003, 278:35718-35724.
25. Zhang Y., Li S., Yuan L., Tian Y., Weidenfeld J., Yang J., et al. Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes Dev 2010, 24:1746-1757.
26. Cohen E.D., Wang Z., Lepore J.J., Lu M.M., Taketo M.M., Epstein D.J., et al. Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. J Clin Invest 2007, 117:1794-1804.
27. Lu S.Y., Jin Y., Li X., Sheppard P., Bock M.E., Sheikh F., et al. Embryonic survival and severity of cardiac and craniofacial defects are affected by genetic background in fibroblast growth factor-16 null mice. DNA Cell Biol 2010, 29:407-415.
28. Jamsheer A., Smigiel R., Jakubiak A., Zemojtel T., Socha M., Robinson P.N., et al. Further evidence for FGF16 truncating mutations as the cause of X-linked recessive fusion of metacarpals 4/5. Birth Defects Res A Clin Mol Teratol 2014, 100:314-318.
29. Jamsheer A., Zemojtel T., Kolanczyk M., Stricker S., Hecht J., Krawitz P., et al. Whole exome sequencing identifies FGF16 nonsense mutations as the cause of X-linked recessive metacarpal 4/5 fusion. J Med Genet 2013, 50:579-584.
30. Laurell T., Nilsson D., Hofmeister W., Lindstrand A., Ahituv N., Vandermeer J., et al. Identification of three novel FGF16 mutations in X-linked recessive fusion of the fourth and fifth metacarpals and possible correlation with heart disease. Mol Genet Genomic Med 2014, 10.1002/mgg3.81.
31. Hawkins RE S.A.-M. Efficient transgene regulation from a single tetracycline-controlled positive feedback regulatory system. Gene Ther 1998, 5:76-84.
32. Miyake A., Konishi M., Martin F.H., Hernday N.A., Ozaki K., Yamamoto S., et al. Structure and expression of a novel member, FGF-16, on the fibroblast growth factor family. Biochem Biophys Res Commun 1998, 243:148-152.
33. Francois M., Koopman P., Beltrame M. SoxF genes: key players in the development of the cardio-vascular system. Int J Biochem Cell Biol 2010, 42:445-448.
34. Sakamoto Y., Hara K., Kanai-Azuma M., Matsui T., Miura Y., Tsunekawa N., et al. Redundant roles of Sox17 and Sox18 in early cardiovascular development of mouse embryos. Biochem Biophys Res Commun 2007, 360:539-544.
35. Zorn A.M., Barish G.D., Williams B.O., Lavender P., Klymkowsky M.W., Varmus H.E. Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. Mol Cell 1999, 4:487-498.
36. Sontag D.P. Characterization of fibroblast growth factor-16 expression and biological function in the heart 2005, [Ph.D.], University of Manitoba, Winnipeg.
37. Antoine M., Wirz W., Tag C.G., Gressner A.M., Wycislo M., Muller R., et al. Fibroblast growth factor 16 and 18 are expressed in human cardiovascular tissues and induce on endothelial cells migration but not proliferation. Biochem Biophys Res Commun 2006, 346:224-233.
38. Sofronescu A.G., Detillieux K.A., Cattini P.A. FGF-16 is a target for adrenergic stimulation through NF-kappaB activation in postnatal cardiac cells and adult mouse heart. Cardiovasc Res 2010, 87:102-110.
39. Colvin J.S., Feldman B., Nadeau J.H., Goldfarb M., Ornitz D.M. Genomic organization and embryonic expression of the mouse fibroblast growth factor 9 gene. Dev Dyn 1999, 216:72-88.
40. Ohmachi S., Watanabe Y., Mikami T., Kusu N., Ibi T., Akaike A., et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem Biophys Res Commun 2000, 277:355-360.
41. Sofronescu A.G., Jin Y., Cattini P.A. A myocyte enhancer factor 2 (MEF2) site located in a hypersensitive region of the FGF16 gene locus is required for preferential promoter activity in neonatal cardiac myocytes. DNA Cell Biol 2008, 27:173-182.
42. Munoz J.P., Collao A., Chiong M., Maldonado C., Adasme T., Carrasco L., et al. The transcription factor MEF2C mediates cardiomyocyte hypertrophy induced by IGF-1 signaling. Biochem Biophys Res Commun 2009, 388:155-160.
43. Zang M.X., Li Y., Wang H., Wang J.B., Jia H.T. Cooperative interaction between the basic helix-loop-helix transcription factor dHAND and myocyte enhancer factor 2C regulates myocardial gene expression. J Biol Chem 2004, 279:54258-54263.
44. Dodou E., Verzi M.P., Anderson J.P., Xu S.M., Black B.L. Mef2c is a direct transcriptional target of ISL1 and GATA factors in the anterior heart field during mouse embryonic development. Development 2004, 131:3931-3942.
45. Zheng M., Zhu J., Lv T., Liu L., Sun H., Tian J. Bone morphogenetic protein2 enhances the expression of cardiac transcription factors by increasing histone H3 acetylation in H9c2 cells. Mol Med Rep 2013, 7:953-958.
46. van Rooij E., Fielitz J., Sutherland L.B., Thijssen V.L., Crijns H.J., Dimaio M.J., et al. Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circ Res 2010, 106:155-165.
47. Li T., Li Y.M., Jia Z.Q., Chen P., Ma K.T., Zhou C.Y. Carboxyl terminus of Nkx2.5 impairs its interaction with p300. J Mol Biol 2007, 370:976-992.
48. Poizat C., Sartorelli V., Chung G., Kloner R.A., Kedes L. Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. Mol Cell Biol 2000, 20:8643-8654.
49. Sepulveda J.L., Belaguli N., Nigam V., Chen C.Y., Nemer M., Schwartz R.J. GATA-4 and Nkx-2.5 coactivate Nkx-2 DNA binding targets: role for regulating early cardiac gene expression. Mol Cell Biol 1998, 18:3405-3415.
50. Ueyama T., Kasahara H., Ishiwata T., Nie Q., Izumo S. Myocardin expression is regulated by Nkx2.5, and its function is required for cardiomyogenesis. Mol Cell Biol 2003, 23:9222-9232.
51. Chen Y., Cao X. NFAT directly regulates Nkx2-5 transcription during cardiac cell differentiation. Biol Cell 2009, 101:335-349.
52. Moskowitz I.P., Kim J.B., Moore M.L., Wolf C.M., Peterson M.A., Shendure J., et al. A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell 2007, 129:1365-1376.
53. Lien C.L., McAnally J., Richardson J.A., Olson E.N. Cardiac-specific activity of an Nkx2-5 enhancer requires an evolutionarily conserved Smad binding site. Dev Biol 2002, 244:257-266.
54. Itoh N., Ohta H. Pathophysiological roles of FGF signaling in the heart. Front Physiol 2013, 4:247.
55. Kardami E., Detillieux K., Ma X., Jiang Z., Santiago J.J., Jimenez S.K., et al. Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 2007, 12:267-277.
56. Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006, 281:15694-15700.
57. Matsumoto E., Sasaki S., Kinoshita H., Kito T., Ohta H., Konishi M., et al. Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking Fgf16. Genes Cells 2013, 18:544-553.
58. House S.L., Melhorn S.J., Newman G., Doetschman T., Schultz Jel J. The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2. Am J Physiol Heart Circ Physiol 2007, 293:H354-H365.
59. Sheikh F., Sontag D.P., Fandrich R.R., Kardami E., Cattini P.A. Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts. Am J Physiol Heart Circ Physiol 2001, 280:H1039-H1050.
60. Santiago J.J., McNaughton L.J., Koleini N., Ma X., Bestvater B., Nickel B.E., et al. High molecular weight fibroblast growth factor-2 in the human heart is a potential target for prevention of cardiac remodeling. PLOS ONE 2014, 9:e97281.
61. Octavia Y., Tocchetti C.G., Gabrielson K.L., Janssens S., Crijns H.J., Moens A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012, 52:1213-1225.
62. Peng X., Chen B., Lim C.C., Sawyer D.B. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 2005, 5:163-171.
63. Horenstein M.S., Vander Heide R.S., L'Ecuyer T.J. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 2000, 71:436-444.
64. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009, 61:154-171.
65. Xu M.F., Tang P.L., Qian Z.M., Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 2001, 68:889-901.
66. Sontag D.P., Wang J., Kardami E., Cattini P.A. FGF-2 and FGF-16 protect isolated perfused mouse hearts from acute doxorubicin-induced contractile dysfunction. Cardiovasc Toxicol 2013, 13:244-253.
67. Huan M., Tian S., Cui H., Zhang B., Su D., Wang J., et al. Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates. BioMed Res Int 2013, 2013:926584.
68. Aries A., Paradis P., Lefebvre C., Schwartz R.J., Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A 2004, 101:6975-6980.
69. Toko H., Zhu W., Takimoto E., Shiojima I., Hiroi Y., Zou Y., et al. Csx/Nkx2-5 is required for homeostasis and survival of cardiac myocytes in the adult heart. J Biol Chem 2002, 277:24735-24743.
70. Clarke M.S., Caldwell R.W., Chiao H., Miyake K., McNeil P.L. Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ Res 1995, 76:927-934.
71. Jimenez S.K., Jassal D.S., Kardami E., Cattini P.A. A single bout of exercise promotes sustained left ventricular function improvement after isoproterenol-induced injury in mice. J Physiol Sci 2011, 61:331-336.
72. Chang S.W., Mislankar M., Misra C., Huang N., Dajusta D.G., Harrison S.M., et al. Genetic abnormalities in FOXP1 are associated with congenital heart defects. Hum Mutat 2013, 34:1226-1230.
73. Komuro I., Izumo S. Csx: a murine homeobox-containing gene specifically expressed in the developing heart. Proc Natl Acad Sci U S A 1993, 90:8145-8149.
74. Danilenko D.M., Montestruque S., Philo J.S., Li T., Hill D., Speakman J., et al. Recombinant rat fibroblast growth factor-16: structure and biological activity. Arch Biochem Biophys 1999, 361:34-46.
75. Basu M., Mukhopadhyay S., Chatterjee U., Roy S.S. FGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway. J Biol Chem 2014, 289:1415-1428.
76. Bailly K., Soulet F., Leroy D., Amalric F., Bouche G. Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. FASEB J 2000, 14:333-344.
77. Jiang Z.S., Srisakuldee W., Soulet F., Bouche G., Kardami E. Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovasc Res 2004, 62:154-166.
78. Schneider M.D., Parker T.G. Cardiac growth factors. Prog Growth Factor Res 1991, 3:1-26.